|
|
|
|
|
|
|
|
|
Medical Device Companies |
Diagnostic Companies | Organizations
| Search Profiles
|
Celera Corporation
1401 Harbor Bay Parkway
Alameda
California
94502
U.S.A.
Phone:
510-749-4200
Fax:
n/a
|
Celera Corporation, acquired by Quest Diagnostics in May 2011, is a healthcare business that uses knowledge of human variability to provide new tests and services to personalize disease management. Our Products business develops and manufactures molecular diagnostic products that are used by hospitals and other clinical laboratories to detect, characterize, monitor and select treatment for disease. We have a distribution agreement with Abbott, through which we develop and commercialize a wide range of molecular diagnostic products, with Abbott serving as the distribution partner.
Our Services business, Berkeley HeartLab, Inc. (BHL), is a high complexity CLIA certified laboratory that offers over 25 clinical diagnostic tests including assays that determine lipoprotein particle size and density based on our proprietary segmented gradient gel electrophoresis technology, along with state-of-the-art genetic testing. These tests identify and characterize risk for cardiovascular disease and help physicians recommend treatment. Our 4myheart centers are staffed with medical professionals who use results from testing at BHL to work with patients, under their physician’s direction, to develop customized regimens for exercise, nutrition, stress management and therapy compliance.
Our internal research and partnering activities fuel the development of new diagnostic tests for personalizing disease management. These new tests are offered as products and/or services.
Email:
webmaster@celera.com
Ownership:
Public
Web Site:
Celera Corporation
Employees:
Symbol: CRA
|
| Collaborations |
|
Seattle Genetics, Inc.
Seeking to jointly discover and develop antibody-based therapies for cancer.
|
|
Aventis Pharmaceuticals, Inc.
Aventis is investigating the use of Cathepsin S inhibitors in a number of therapeutic areas related to inflammation and autoimmune disease.
|
|
Maxim Pharmaceuticals, Inc.
Collaboration to identify and develop novel small-molecule compounds that induce apoptosis, potential new therapies for certain cancers.
|
|
Abbott Laboratories
Broad program to discover, develop and commercialize therapies for the treatment of cancer, including therapeutic antibodies and small molecules.
|
|
Merck & Co., Inc.
Genome databases, Alzheimer's disease, Diagnostics
|
|
|
 |
|
|
|
|
|
|
|
|